SCHEMBL5135840

SCHEMBL5135840

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(S)cc1)Cc1ccc2c(c1)OC(F)(F)O2

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.51
TSHR P16473 3/20 0.35
UBE2M P61081 1/20 0.32
DCUN1D1 Q96GG9 1/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
PDE4B Q07343 3/20 0.31
CRHR1 P34998 2/20 0.31
HSD11B1 P28845 2/20 0.31
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
NR1H3 Q13133 1/20 0.30
DRD4 P21917 1/20 0.30
CYP3A4 P08684 1/20 0.30
HDAC1 Q13547 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649922 0.95 C5AR1 (0.54) C5AR1TSHRUBE2MDCUN1D1KDM4E
SCHEMBL5134619 0.91 C5AR1 (0.54) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL649848 0.91 C5AR1 (0.53) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135062 0.91 C5AR1 (0.53) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL650008 0.90 C5AR1 (0.49) C5AR1TSHRKDM4EALDH1A1HSD17B10
SCHEMBL649410 0.88 C5AR1 (0.47) C5AR1TSHRLMNASMN1; SMN2
SCHEMBL651417 0.88 C5AR1 (0.47) C5AR1TSHRUBE2MDCUN1D1ALDH1A1
SCHEMBL649285 0.87 C5AR1 (0.49) C5AR1TSHRUBE2MDCUN1D1KDM4E
SCHEMBL5136214 0.86 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL650915 0.85 C5AR1 (0.49) C5AR1TSHRUBE2MDCUN1D1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed